Incidence and progression of diabetic retinopathy in patients treated with glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter 2 inhibitors: A population‐based cohort study
Main finding · DR progression composite in patients with pre-existing DRResult — go to the resultSubdistribution hazard ratio 1.50 95% CI 1.01–2.23Authors' conclusion
In patients with diabetes mellitus and established DR, GLP1RA treatment was associated with increased risks of DR progression compared with SGLT2i use.
Study context
- Population
- Patients with diabetes initiating GLP-1 RA or SGLT2i between 1 May 2016 and 31 December 2017, with or without previous diabetic retinopathy (DR) diagnosis; nationwide databaseidentified before matching
- Participants
- 97,413 patients
- Exposure
- GLP-1 RA vs SGLT2i initiation
- Outcome
- DR cohort: composite of new-onset proliferative DR, vitreous haemorrhage and tractional retinal detachment; non-DR cohort: composite of newly diagnosed DR of any severity, vitreous haemorrhage and retinal detachment
Methodological detailspopulation-based, nationwide database, matched
- Population-based
- Nationwide database
- Matched
Main finding
As reported in the abstract
DR progression composite in patients with pre-existing DR
Subdistribution hazard ratio
1.50
95% CI 1.01–2.23
GLP1RAvs SGLT2i
subdistribution HR 1.50 (95% CI 1.01–2.23)
Observational data: associations, not effects.
Further findings
Ocular outcomes in patients without DR at baseline
- Risks of all ocular outcomes similar between GLP1RA and SGLT2i (non-DR cohort: 9549 GLP1RA, 19 098 SGLT2i)
Original publication
Incidence and progression of diabetic retinopathy in patients treated with glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter 2 inhibitors: A population‐based cohort study. Diabetes Obes Metab. Published 19 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →